Information Provided By:
Fly News Breaks for December 7, 2015
PFE, LLY, ABBV, ABT
Dec 7, 2015 | 07:49 EDT
As previously reported, Jefferies analyst Jeffrey Holford upgraded Abbott Laboratories (ABT) to Buy and raised his price target for shares to $55 from $49. Holford believes that Abbott's growth in emerging markets will remain solid given the defensive nature of its products and he expects management to keep driving margin improvement and strong earnings growth. The upgrade of Abbott comes amid a reorganizing of Jefferies' global pharma rankings for 2016, Holford noted, listing AbbVie (ABBV) as the firm's top pick, Eli Lilly (LLY) in second place and Pfizer (PFE) in third place.
News For ABT;ABBV;LLY;PFE From the Last 2 Days
LLY
Mar 18, 2024 | 10:41 EDT
Oprah Winfrey is hosting a television special on Monday to discuss how WeightWatchers (WW) and weight loss drugs helped her with weight and obesity, CNN's Lisa Respers France reports. "An Oprah Special: Shame, Blame and the Weight Loss Revolution" will be a sit-down conversation around the "radical impact of prescription weight loss medications," according to promotional material for the special. Winfrey, who recently exited the board of WW, will moderate the conversation in front of a live audience with medical experts to explore "prevailing questions and concerns surrounding the impact on our health care, economy, lifestyle and culture," according to a press release for the event. "It is a very personal topic for me and for the hundreds of millions of people impacted around the globe who have for years struggled with weight and obesity," Winfrey said. Weight loss drug options include Eli Lilly's (LLY) Mounjaro and Novo Nordisk's (NVO) Ozempic. Reference Link